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Head and neck squamous cell carcinomas (HNSCC) exhibit a small population of uniquely tumorigenic cancer stem cells
(CSC) endowedwith self-renewal andmultipotency.Wehave recently shown that IL-6 enhances the survival and tumorigenic
potential of head and neck cancer stem cells (i.e. ALDHhighCD44high cells). Here, we characterized the effect of therapeutic
inhibition of IL-6 with a novel humanized anti-IL-6 antibody (MEDI5117) using three low-passage patient-derived xenograft
(PDX) models of HNSCC. We observed that single agent MEDI5117 inhibited the growth of PDX-SCC-M1 tumors (P b .05).
This PDX model was generated from a previously untreated HNSCC. In contrast, MEDI5117 was not effective at reducing
overall tumorvolumeforPDXmodelsrepresentingresistantdisease(PDX-SCC-M0,PDX-SCC-M11).LowdoseMEDI5117(3mg/kg)
consistently decreased the fraction of cancer stem cells in PDXmodels of HNSCCwhen compared to IgG-treated controls,
as follows: PDX-SCC-M0 (P b .001), PDX-SCC-M1 (P b .001), PDX-SCC-M11 (P= .04). Interestingly, high doseMEDI5117
(30 mg/kg) decreased the CSC fraction in the PDX-SCC-M11 model (P= .002), but not in PDX-SCC-M0 and PDX-SCC-M1.
MEDI5117 mediated a dose-dependent decrease in the number of orospheres generated by ALDHhighCD44high cells
cultured in ultra-low attachment plates (P b .05), supporting an inhibitory effect on head and neck cancer stemcells. Notably,
single agent MEDI5117 reduced the overall recurrence rate of PDX-SCC-M0, a PDX generated from the local recurrence of
human HNSCC. Collectively, these data demonstrate that therapeutic inhibition of IL-6 with low-doseMEDI5117 decreases
the fraction of cancer stem cells, and that adjuvant MEDI5117 inhibits recurrence in preclinical models of HNSCC.
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Head and neck squamous cell carcinoma (HNSCC) is a major health
concern in the United States, with more than 40,000 new cases every
year [1]. The standard of care for HNSCC includes intense
platinum-based chemotherapy, complete surgical resection of the
tumor (if possible), and radiotherapy [2]. Despite significant advances
in treatment, the average 5-year survival for HNSCC patients has
remained around 50% to 60% for the last 30 years [3]. Recognizing
that the common causes of morbidity for patients with HNSCC is
disseminated disease, recent research has focused on the understand-
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better therapeutic targets. These studies led to the discovery of a small
population of uniquely tumorigenic, multipotent cancer cells
endowed with self-renewal, named cancer stem cells (CSC) [4,5].
These cells drive the tumorigenic process of HNSCC [6], and have
recently become a conceptual target for therapy for patients with head
and neck cancer. Considering the prominent role that cancer stem
cells have on the dissemination of HNSCC [7], it is likely that
patients with HNSCC will benefit from their targeted elimination.
Cancer stem cells proliferate slowly and are resistant to conventional
therapies [8,9]. Indeed, we have recently observed thatCisplatin, themost
frequently used chemotherapy for HNSCC, causes an increase in the
CSC fraction in preclinical models [10]. Cisplatin treatment results in
selective elimination of non-CSC as well as an increase in the self-renewal
of CSCs, as demonstrated by enhanced expression of the major
self-renewal regulator Bmi-1. These data led to the hypothesis that
combination therapy with a tumor de-bulking strategy (e.g. chemoradi-
ation) combined with an anti-cancer stem cell agent could provide amore
durable response and enhance the survival of HNSCC patients [11].
Cancer stem cells are typically found in specialized niches, i.e.
unique functional microenvironments that provide the cues required
for survival and self-renewal of these cells [12,13]. We have observed
that the majority of head and neck CSC are within close proximity of
blood vessels, suggesting that these cells reside in perivascular niches
[14]. Interestingly, endothelial cell-secreted factors, e.g. interleukin-6
(IL-6) and epidermal growth factor (EGF), activate key signaling
pathways that protect CSC from anoikis and enhance their invasive
potential [15–17]. Further, IL-6 is more highly expressed in the
vascular endothelial cells of head and neck tumors than in the tumor
cells themselves [17]. IL-6 activates the STAT signaling pathway via
the JAK kinase. The activation of JAK leads to downstream
phosphorylation of the STAT3, which is translocated to the nucleus
to regulate genes critical in controlling cell proliferation, differenti-
ation, and survival signals [18]. We have recently shown that
endothelial cell-secreted IL-6 enhances the tumorigenic potential and
self-renewal of head and neck CSC [17]. In addition, IL-6 potentiates
the inductive effect of Cisplatin on the self-renewal of CSC, resulting
in accumulation of these cells [10]. From a clinical perspective, a
strong correlation between high serum IL-6 levels with poor survival
of head and neck cancer patients has been reported [19].
Collectively, these studies provide strong rationale for the
development of anti-IL-6 therapies for treatment of patients with
HNSCC. Here, we evaluated the effect of MEDI5117, a novel
humanized monoclonal antibody with high affinity for IL-6 [20], on
the CSC fraction and recurrence of patient-derived xenograft (PDX)
tumor models of HNSCC. MEDI5117 was generated by variable
domain engineering (to enhance its affinity for IL-6), in combination
with the use of Fc (fragment crystallizable) engineering that aimed at
enhancing the half-life of the antibody and therefore allowing for
lower frequency of administration [20]. Indeed, MEDI5117 might be
considered an example of a “next-generation” antibody that could be
well suited for long-term use as a CSC-targeting strategy since it is not
associated with significant systemic toxicities.
Materials and Methods
Patient-Derived Xenograft (PDX) Tumor Models of HNSCC
Patient-derived xenograft (PDX) tumor models (PDX-SCC-M series)
were generated fromHNSCC tumors that were surgically resected betweenAugust/2012 and May/2013 at the University of Michigan (Supplemen-
tary Figure 1). The collection and handling of these specimens was
performed under signed, informed consent and approval from appropriate
institutional review boards. Tumorswereminced into small pieces (4mm×
4mm) andwashed 2–3 times in primary tumormedium consisting of high
glucose Dulbecco’s Modified Eagle’s Medium (DMEM; Invitrogen;
Carlsbad, CA, USA), supplemented with 1% L-glutamine (Invitrogen),
10% Fetal Bovine Serum (Invitrogen), 20 ng/ml rhEGF (Sigma-Aldrich;
St. Louis,MO,USA), 400 ng/ml hydrocortisone (Sigma-Aldrich), 5μg/ml
insulin (Sigma-Aldrich), 50 mg/ml Nystatin (Sigma-Aldrich), antibioti-
c-antimycotic (AAA; Sigma-Aldrich) and amphotericin-B (Sigma-Aldrich).
After washing, tumor fragments were transplanted into the subcuta-
neous space of the dorsal region of severe combined immunodeficient
mice (CB-17 SCID; Charles River; Wilmington, MA, USA). Tumors
were surgically retrieved when they reached 700 to 1000 mm3, and
passed serially into new mice. Notably, all experiments included here
were performed in PDX tumors at in vivo passage 6 or lower. Tumor,
liver, and lung tissues were retrieved and fixed overnight in 10%
phosphate-buffered formalin (Fisher; Waltham, MA, USA) at 4°C and
processed for immunohistochemistry.
Short-Tandem Repeat (STR) Profiling
To verify the identity of the PDX models over several in vivo
passages, genomic DNA from the patient’s tumor or Passage 0
xenograft (reference) and subsequent passages of xenograft tumors
was purified using the Wizard Genomic DNA Purification Kit
(Promega; Madison, WI, USA). DNA genotyping by short tandem
repeat (STR) profiling was performed and analyzed independently by
Genetica LabCorp (Burlington, NC, USA).
TruSeq Amplicon-Cancer Panel (TSACP) Assay
The TruSeq Amplicon-Cancer Panel (TSACP) assay (Illumina;
San Diego, CA, USA) was performed to detect specific mutations in a
panel of 48 cancer-related genes in our PDX models of HNSCC.
Data were analyzed by the MiSeq desktop sequencer (Illumina), as
recommended by the manufacturer.
MEDI5117 Treatment
Mice harboring PDX tumors (approximately 200 mm3) were
treated with 3 or 30 mg/kg MEDI5117 (MedImmune; Gaithersburg,
MD, USA) injected intraperitoneally, two times per week, for 3 to 7
weeks to evaluate the effect of this antibody on tumor growth and
cancer stem cell fraction. Alternatively, tumors were allowed to grow
to approximately 700 mm3 and then surgically removed to evaluate
the effect of MEDI5117 on tumor recurrence.
Immunofluorescence
For CSC staining, tissues were exposed to 3% hydrogen peroxide
(Fisher), and incubated overnight at 4°C with a rabbit anti-ALDH1
antibody (1:50; Abcam; Cambridge, MA, USA). ALDH1 signal was
detected with Alexafluor 488 secondary antibody (1:200; Invitrogen).
Then, tissues were incubated with a mouse anti-CD44 antibody (Thermo
Scientific; Wayne, MI, USA). CD44 signal was detected with Alexafluor
594 secondary antibody (1:200; Invitrogen). Slides were mounted with
ProLongGold Anti-fade Reagent withDAPI (Invitrogen) before imaging.
Head and Neck Cancer Stem Cell Sorting
Primary human HNSCC specimens were cut and minced with a
sterile scalpel until they could pass through a 25 ml pipette. They
were dissociated using the GentleMACS kit (Miltenyi; Bergisch
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were filtered through a 40-μm nylon sieve (BD Biosciences, San Jose,
CA, USA), washed with DMEM, and centrifuged at 800 RPM, 4°C
for 5 minutes. Red blood cells were lysed for 1 minute using 5 ml
AKC lysing buffer (Invitrogen) and centrifuged at 800 RPM, 4°C for
5 minutes. Resulting single cell suspensions were washed, counted,
and resuspended at 1 × 106 cells/ml in PBS. The Aldefluor kit (Stem
Cell Technologies; Vancouver, BC, Canada) was used to identify cells
with high ALDH activity. Briefly, cells were suspended in activated
BAAA-DA substrate or in a specific ALDH inhibitor (DEAB, StemCell
Technologies) for 45 minutes at 37°C. Cells were then exposed to
anti-CD44 (clone G44-26, BD Biosciences; San Jose, CA, USA) and
HLA-ABC to select for human cells. Finally, 7-Aminoactinomycin
(7-AAD; BD Biosciences) was used to eliminate non-viable cells.
Cancer stem cells were identified as the subpopulation of cells
expressing high levels of ALDH and CD44, as we have shown
previously [14,17].
Enzyme-Linked Immunosorbent Assay (ELISA)
Nunc Maxisorb plates (eBioscience; San Diego, CA, USA) were
coated with 100 μl of 1 μg/ml MEDI5117 and incubated overnight
at 4°C. After 4 washes, 100 μl of standard (eBioscience) or tumor
lysate was added to the plates. We sealed the plates and incubated
them for 2 hours at room temperature. Washed cells were then
exposed to 100 μl of detection antibody (Cell Sciences; Canton, MA,
USA) and incubated for 1 additional hour at room temperature.
Following this incubation, plates were again washed. We added 100 μl
Avidin-HRP (eBioscience) to each plate and incubated at room
temperature for 30minutes. After a final wash, 100μl of TMB substrate
solution (eBioscience) was added to the wells. After 15minutes, 50μl of
stop solution was added to the plates. Absorbance was measured
immediately on a microplate reader at 450 nm with a subtraction of
562 nm (Genios Tecan; Salzburg, Austria). Triplicate wells per
tumor lysate were evaluated.
Sulforhodamine-B (SRB) Assay
For these studies, we plated 2 × 103 HNSCC cells per well
(UM-SCC-11B or UM-SCC-22B, kindly provided by Dr. T. Carey)
and exposed them to 0.01 to 100 μg/ml MEDI5117 or 100 μg/ml
control IgG (R347). After 24 to 72 hours, cells were fixed with 50%
trichloroacetic acid and stained with 0.4% sulforhodamine-B solution
(SRB; Sigma Aldrich). Unbound SRB dye was removed by washing
with 1% acetic acid. Plates were air-dried and bound SRB was
resolubilized in 10 mM unbuffered Trizma base. Absorbance was
analyzed on a microplate reader at 560 nm (Genios Tecan). Test
results were normalized against initial plating density and IgG
controls. Quadruplicate wells per condition were evaluated and are
representative of at least two independent experiments.
Orosphere Assay
Non-adherent spheroids of head and neck cancer stem-like cells
(named orospheres) were generated from FACS-sorted
UM-SCC-22B cells (1 × 103 cells/well) and cultured in triplicate
wells in 24-well ultra-low attachment plates (Corning, Corning, NY,
USA), as we have shown previously [21]. Briefly, cells were cultured
in DMEM/F12 (Invitrogen) supplemented with 1% N2 (Invitro-
gen), 10 ng/ml EGF (Sigma-Aldrich), and 10 ng/ml basic Fibroblast
Growth Factor (bFGF; EMD Millipore, Temecula, CA, USA). After 3
days, orospheres (defined as spheres of ≥25 cells) were visualized andquantified under light microscopy, then treated with 0.01 to 100 μg/ml
MEDI5117 (MedImmune) or 100 μg/ml IgG control (MedImmune).
After 3 to 5 additional days, orospheres were again visualized and
quantified under light microscopy. Alternatively, cells were treated with
MEDI5117 or IgG control at the time of plating. After 3 to 7 days,
orospheres were visualized and quantified under light microscopy.
Statistical Analyses
Data were analyzed by one-way analysis of variance (ANOVA)
followed by appropriate post-hoc tests. Kaplan Meier analyses were
performed to determine the effect of treatment on time to tumor
recurrence. Statistical significance was determined at P b .05. These
analyses were performed using the SigmaStat 2.0 software (SPSS;
Chicago, IL, USA).
Results
Characterization of the PDX Models of Head and Neck
Squamous Cell Carcinoma
To generate patient-derived xenograft (PDX) models of HNSCC,
we implanted small fragments of the primary tumor directly in the
subcutaneous space of immunodeficient mice. The primary tumors
used to generate the PDX models represent diverse clinical
characteristics typically observed in patients with HNSCC. The
PDX-SCC-M1 model was generated from the primary tumor of a
patient that was previously untreated. The PDX-SCC-M0 model was
generated from the local recurrence of a patient that had incomplete
resection of the primary tumor without radiation or chemotherapy.
Lastly, the PDX-SCC-M11 model represents a local recurrence of a
primary tumor in the sinonasal cavity of a patient who previously
underwent treatment with surgery, radiation, and chemotherapy with
TPF (Docetaxel, Carboplatin, 5-Fluorouracil) (Supplementary Figure 1).
The rationale for selecting these 3 models is based on our intent to
rigorously test the effect of MEDI5117 across a spectrum of different
possible clinical manifestations of HNSCC. We performed serial
passaging of the PDX tumors for up to 8 in vivo passages (Figure 1A),
but only used PDX tumors up to passage 6 for the testing of
MEDI5117. The overall micromorphology of the PDX tumor
models across numerous passages was consistent with the original
human tumors (Figure 1B). As we have shown with salivary gland
cancer [22], overall trends of faster tumor growth (Figure 1A) and
enhanced tumor take (data not shown) were observed with increased
in vivo passaging of the PDX models. To determine if the PDX
models are reflective of their primary source, and to evaluate potential
genetic drifts over time, short tandem repeat (STR) profiling was
performed (Supplementary Figure 2A). Based on the analysis of 15
autosomal loci and the gender identity locus Amelogenin, the STR
profiles for PDX-SCC-M0 and PDX-SCC-M11 showed 100%
match against the respective reference samples. We observed minimal
allelic loss (94.3% match) in the PDX-SCC-M1 model. This
phenomenon has been reported as the result of a mouse DNA
increase relative to the human DNA content, which typically happens
in xenograft tumors [23]. Notably, all three patient samples used for
generation of the PDX models characterized here were negative for
HPV16 (data not shown), which typically correlates with head and
neck tumors that are resistant to therapy [24].
To begin to characterize the mutational landscape of our PDX
models of HNSCC, we performed targeted sequencing using the
MiSeq platform. We used the Cancer Panel from Illumina and
therefore the genes that were sequenced constitute a panel of 48 of the
Figure 1. Characterization of the PDX models of head and neck squamous cell carcinoma. (A) Graphs depicting tumor growth over time.
Lines represent the median tumor volumes within each passage of the PDX models of HNSCC used here. (B) H&E staining of the original
human tumor and correspondent PDX-SCC-M0 model at passage 0, 1 and 5. Please note that the overall micromorphology of the PDX
tumor closely resembles the morphology of the human tumor used to generate the PDX model.
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PDX-SCC-M0 exhibited a non-synonymous mutation of AKT1 that
was carried through from Passage 0 to Passage 5 xenografts
(Supplementary Figure 2B). Three mutations (TP53, FGFR3,
GNAS) were observed in PDX-SCC-M1 tumors. Notably, all of
these mutations are in genes that regulate critical cell survival and
differentiation pathways. For example, TP53 is a key regulator of cell
apoptosis and it is the most frequently mutated gene in HNSCC [25].
Low Dose MEDI5117 Decreases the Fraction of Cancer Stem
Cells in PDX Models of Head and Neck Squamous Cell
Carcinoma
We have previously shown that ALDHhighCD44high cells sorted
from HNSCC are multipotent, exhibit self-renewal, and are highly
tumorigenic, characterizing this sub-population as cancer stem cells
[14]. We used low-passage (up to passage 6) PDX models to evaluate
if treatment with MEDI5117 affects tumor growth and the fraction
of CSC. The PDX tumors consistently showed high fractions of
CD44-positive cells, and few ALDH1-positive cells (Figure 2).
Treatment with single agent MEDI5117 caused a significant
inhibition of tumor growth in the PDX-SCC-M1 model, but not
in the PDX-SCC-M0 or PDX-SCC-M11 models (Figure 3A;Supplementary Figure 3). As expected, MEDI5117 reduced the
levels of circulating free IL-6 (Supplementary Figure 4). MEDI5117
at a dose of 3 mg/kg consistently caused a decrease in the fraction of
cancer stem cells (ALDHhighCD44high) in the PDX-SCC-M11
model (P = .04), PDX-SCC-M1 model (P b .001) and
PDX-SCC-M0 (P b .001) (Figure 3C). Surprisingly, at the higher
dose of 30 mg/kg, MEDI5117 caused a decrease in cancer stem cell
fraction in the PDX-SCC-M11 model (P = .002), but not in the
PDX-SCC-M0 or PDX-SCC-M1models (P N .05) (Figure 3C). Both
regimens for MEDI5117 were very well tolerated by the mice, as
demonstrated by the absence of noticeable weight loss (compared to
IgG controls) for the duration of the experiments, i.e. up to 126 days
(Figure 3B).
Effects of MEDI5117 on Sorted and Unsorted HNSCC Cells
To evaluate the effect of MEDI5117 on the proliferation/survival
of HNSCC cells, we exposed two established cell lines
(UM-SCC-11B, UM-SCC-22B) to increasing concentrations of the
antibody and performed the SRB assay. We observed that
MEDI5117 did not show a demonstrable impact on unsorted
HNSCC cell density (Figure 4A). We repeated this assay with low
passage primary cells that outgrew from the PDX tumors models used
Figure 2. Expression of ALDH1 and CD44 in a PDX model of HNSCC. Immunofluorescence staining of ALDH1 (green) and CD44 (red) in
histological sections of the PDX-SCC-M0 model at 200× and 400× magnifications. White arrowheads point to ALDHhighCD44high cells.
Please note the cytoplasmic localization of ALDH1 and the cell membrane localization of CD44. DAPI (blue) was used to identify cell
nuclei.
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cells (data not shown).
To evaluate the effect of MEDI5117 on CSC, we used the
orosphere assay with cells sorted for ALDH and CD44 grown in
ultra-low attachment plates [21]. We observed a significant decrease
in the number of orospheres when MEDI5117 was added to the
medium at the time of cell plating (Figure 4B). To challenge these
results, we repeated this experiment but now we allow the orospheres
to form for 3 days and then we added MEDI5117. We observed that
MEDI5117 was able to disrupt the orospheres causing a significant
decrease in their number (Figure 4B). Notably, control non-CSC
ALDHlowCD44low cells formed very few orospheres under low
attachment conditions, and no effect for MEDI5117 was observed in
these cells (Figure 4B). Collectively, this set of experiments
demonstrated that MEDI5117 has a more prominent effect on the
cancer stem cells, as compared to broad effects in the bulk cells.
Next, we examined the effect of MEDI5117 on the activation of
the STAT3 pathway in HNSCC cells (Figure 4C). UM-SCC-11B
and UM-SCC-22B were starved overnight before being exposed to
recombinant human IL-6 (rhIL-6) in presence of MEDI5117 or IgG.
As expected, exposure to rhIL-6 resulted in STAT3 phosphorylation.
MEDI5117 mediated a potent decrease in STAT3 phosphorylation
in both cell lines in vitro. The same phenomenon was observed in vivo,
in PDX-SCC-M11 tumors from mice treated with MEDI5117
(Figure 4D). We also observed some decrease in expression of the
receptor IL-6R in mice treated with MEDI5117 (Figure 4D).
MEDI5117 Prevents Tumor Recurrence When Used in the
Adjuvant Setting
Considering the emerging evidence demonstrating a prominent
role for cancer stem cells in HNSCC tumor cell invasion [16,26] anddissemination [7], we designed pre-clinical trials intended to verify
the effects of MEDI5117 on HNSCC recurrence (Figure 5).
PDX-SCC-M0 tumors were allowed to grow up to a mean volume
of 700 mm3 before being surgically resected (Figure 5A). MEDI5117
was administered either in a neoadjuvant setting (treatment started 2
days prior to surgery) or adjuvant setting (treatment started 1 day
after surgery). Mice from both groups were treated equally with
MEDI5117 thereafter. The IgG control group received its first dose 1
day following surgical resection of the tumors, mimicking the
adjuvant setting. Treatment with MEDI5117 continued twice weekly
for seven weeks following tumor resection, and mice were monitored
two times per week for tumor recurrence for up to 100 days. A
Kaplan-Meier analysis was performed using the presence of a palpable
tumor (Supplementary Figure 5) as criteria for tumor recurrence. We
observed that MEDI5117 in the adjuvant setting did not allow any
tumor recurrence (0 out of 9 mice with palpable tumors) for at least
100 days after surgical removal of the original tumor (P = .0068)
(Figure 5C). In contrast, tumor recurrence was observed when
MEDI5117 was used in the neoadjuvant setting (4 out of 10) and
when IgG control was used (P = .2485) (6 out of 10) (Figure 5C).
Notably, when all MEDI5117-treated tumors were grouped together
(19 tumors), we observed a significant (P = .0172) inhibition of
tumor recurrence when compared to all IgG control tumors
(Figure 5C).
Discussion
Advanced primary HNSCC initially responds well to chemoradia-
tion. However, a frequent problem with these patients is local
recurrence and/or distant metastases. Emerging evidence supports a
key role for CSC in the dissemination of HNSCC [7,16,26]. Here,
we showed that low dose monoclonal anti-IL-6 antibody reduces the
Figure 3. Low dose MEDI5117 decreases the fraction of cancer stem cells in PDX models of HNSCC. (A) Graphs depicting mean tumor
growth over time in mice treated with 3 or 30 mg/kg MEDI5117, as compared to treatment with IgG control. Arrows denote the timing for
the beginning of treatment with MEDI5117 or IgG control. (B) Graphs depicting mean mouse weight according to treatment conditions
over time. (C) Graphs depicting the percentage of ALDHhighCD44high cells, as determined by flow cytometry from 5 tumors (PDX-SCC-M1
and PDX-SCC-M11) or 6 tumors (PDX-SCC-M0). Asterisks depict P b .05.
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used in the adjuvant setting after surgical removal of the primary tumor.
These results suggest that patients with HNSCC might benefit from
therapeutic inhibition of IL-6 with a monoclonal antibody.
We developed and characterized 3 new PDX models of HNSCC
for the work presented here. These models were generated from
patients with advanced HNSCC (Stage III or IV) and represent three
distinct clinical scenarios that are relatively common in this patient
population. We believe that these PDX models are representative of
patients that typically do not respond well to treatment, and are
therefore useful for rigorous testing of new therapies. Furthermore,
we have treated only low passage (i.e. less than 6 in vivo passages)
PDX tumors in an attempt to more accurately recapitulate the disease
encountered in a clinical setting. We observed that MEDI5117
inhibited the growth of the PDX-SCC-M1 model that was generated
from a previously untreated patient with advanced HNSCC (StageIII). In contrast, the PDX-SCC-M0 and PDX-SCC-M11 models that
represent previously treated, recurrent tumors were not responsive to
treatment with MEDI5117. These results suggest that MEDI5117
has modest effects on previously treated tumors, and would likely
have to be combined with conventional therapies in these settings.
The analysis of the effect of MEDI5117 in CSC revealed interesting
results. While MEDI5117 had no measurable effect in unsorted
HNSCC cells, we observed consistent inhibitory activity ofMEDI5117
in sorted CSC using the orosphere assay. These data suggest that the
effect of MEDI5117 might be primarily observed in CSC.
Interestingly, we have previously shown that head and neck CSC
(ALDHhighCD44high) express significantly higher levels of IL-6R
than non-CSCs (ALDHlowCD44low) [17], which might explain, at
least in part, the selective effect of MEDI5117 in the CSC population.
We observed that single agent MEDI5117 was sufficient to prevent
tumor growth in the PDX model of previously untreated disease
Figure 4. Effects of MEDI5117 on overall survival, number of orospheres, and STAT3 signaling in HNSCC cells. (A) Graphs depicting the
effect of 0.1-10 μg/mlMEDI5117 on bulk cell survival of unsorted HNSCC cells (UM-SCC-11B, UM-SCC-22B), as determined by SRB assay.
Data were normalized against corresponding IgG controls. (B) Graphs depicting the effect of MEDI5117 on HNSCC cells (UM-SCC-22B)
sorted for ALDH and CD44. Cells were treated with increasing concentrations of MEDI5117 (0.01–10 μg/ml) or 10 μg/ml IgG control either
after formation of orospheres (left panel) or at the time of plating (right panel) in 24-well ultra-low attachment plates (n = 3 wells/
condition). Significance was determined by one-way ANOVA to the control within each day. Asterisks depict P b .05. (C) Western blots
depicting the effect of treatment with MEDI5117 on phospho- and total STAT3 in UM-SCC-11B and UM-SCC-22B cells. Cells were treated
with 0 or 20 ng/ml rhIL-6 in presence of 0 or 10 μg/ml MEDI5117 for 24 hours (D) Western blot depicting the in vivo effect of MEDI5117 on
IL-6R, pSTAT3, and total STAT3 expression in PDX-SCC-M11 tumors from mice treated either with 3 mg/kg MEDI5117 or IgG control.
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tumor growth in the two tumor-resistant PDX models studied here
(PDX-SCC-M0 and PDX-SCC-M11). In such clinical scenario, one
might have to consider combination strategies with conventional
chemotherapeutic drugs. Cisplatin typically causes regression of
previously untreated HNSCC, and therefore it is the most frequently
used chemotherapy in head and neck cancer. The problem is that
advanced HNSCC treated with Cisplatin frequently end up recurringlocally or at distant sites. We have previously shown that Cisplatin
increases the CSC fraction by enhancing their self-renewal particularly
in presence of IL-6 [10]. Considering that CSC cells appear to drive
head and neck tumor recurrence [7,16,26], these results suggest the
possible indication of combination therapy using an anti-IL-6 strategy
and a conventional (de-bulking) chemotherapeutic drug.
We observed that low dose MEDI5117 (3 mg/kg) consistently
decreased the fraction of CSC in all 3 PDX models of HNSCC tested
Figure 5. MEDI5117 prevents tumor recurrence when used in the adjuvant setting. (A) Graph depicting mean tumor growth
(PDX-SCC-M0) over time in mice treated with MEDI5117, as compared to treatment with control IgG. Arrow denotes the timing for the
beginning of treatment with MEDI5117 in the neoadjuvant setting. MEDI5117 was administered either in a neoadjuvant setting (treatment
started 2 days prior to surgery) or adjuvant setting (treatment started 1 day after surgery). Mice from both groups were treated equally
thereafter. The control IgG group received its first dose 1 day following surgical resection of the tumors, mimicking the adjuvant setting.
Survival was defined as recurrence-free mice, as determined by the absence of a palpable secondary tumor mass measuring≤100 mm3.
(B) Graph depicting average mouse weight according to treatment conditions over time. (C) Graph depicting the Kaplan-Meier analysis of
the effect of MEDI5117 on tumor recurrence according to treatment regimen.
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fraction of cancer stem cells in the PDX-SCC-M11 model, which was
generated from a patient that was previously treated with
chemoradiation. These results are surprising, as one would perhaps
expect that the results with higher concentration of MEDI5117
would be aligned with those with the low concentration. Neverthe-
less, when MEDI5117 was used in a PDX model generated from a
previously untreated primary tumor, we observed a significant
decrease in tumor growth rate, suggestive of an effect of
MEDI5117 in both CSC as well as in more differentiated cells.
This might explain why in this case we did not observe significant
differences in the CSC fraction with 30 mg/kg MEDI5117, as the
reduction in the number of CSC and non-CSC might have been
proportionally similar. From these studies we concluded that a low
dose MEDI5117 might be effective in reducing the fraction of CSC
across diverse HNSCC tumors. As indicated above, possible
combination strategies with a chemotherapeutic drug might benefit
from the possibility of using low dose MEDI5117 as a means to
reduce safety concerns while maintaining efficacy.
Perhaps the most intriguing aspect of this work is that the anti-IL-6
antibody eliminated tumor recurrence when used in the adjuvant
setting immediately after surgical removal of the tumor. For these
studies, we selected the PDX-SCC-M0 model generated from arecurrent human tumor as a way to challenge the anti-IL-6 therapy.
Overall, MEDI5117 prevented tumor recurrence for 100 days
post-surgery. When we break down the results by treatment regimen,
we observed that the adjuvant treatment with MEDI5117 eliminated
tumor recurrence, i.e. we had 0 recurrences by 100 days of follow-up
in this group. Neoadjuvant dosing of MEDI5117 showed a trend
(albeit non-significant) for reduction of tumor recurrence. In both
cases, we did not observe significant toxicities despite the fact that the
antibody was used for a long time, as demonstrated by the
maintenance of mouse weight throughout the study. We postulate
that the effect of MEDI5117 in preventing tumor recurrences might
be correlated with its ability to inhibit the tumorigenic function of the
cancer stem cells.
In conclusion, the work presented here represents the first attempt
to determine the effect of the new monoclonal anti-IL-6 antibody
MEDI5117 in head and neck squamous cell carcinoma. We are
encouraged by the inhibitory effects of this antibody on the fraction of
cancer stem cells and on the incidence of recurrence in PDX models
that are representative of human disease. This work also unveiled
important questions that will have to be answered with regard to the
ideal dosing and regimen for maximal effect of this new putative
therapy for HNSCC. While certainly much work still needs to be
done to fully develop an anti-cancer stem cell therapy based on IL-6
Neoplasia Vol. 18, No. 5, 2016 Therapeutic inhibition of IL-6 in head and neck cancer Finkel et al. 281inhibition, these results suggest that patients with head and neck
cancer might benefit from therapeutic blockade of IL-6 signaling.
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